Boundless Bio, Inc. (BOLD): Total Assets
$157.06M
As of 2025-12-31
$73.74M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $157.06M | -23.9% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $206.41M | +58.9% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $129.89M | n/a | 2025-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | 2025-12-31 | $157.06M | -23.9% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $155.50M | +7.0% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $154.69M | +117.6% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $160.43M | +58.2% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $160.46M | -27.2% |
| Veradermics, Inc (MANE) | 2025-12-31 | $152.62M | +174.8% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $162.40M | n/m |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $151.57M | +25.7% |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $163.18M | +232.2% |
Compare BOLD, PGEN, XLO, AQST side by side · Screen every company in Pharmaceutical Preparations ↗